Setting Up a PT PMA for Medical Device Distribution in Indonesia

1. Key takeaways

Can foreign investment operate device distribution in Indonesia? Yes, and with 100 percent shareholding. Pharmaceutical manufacturing and wholesale, medical device distribution, private hospitals and specialist clinics all permit 100 percent foreign ownership; primary clinics (Klinik Pratama) remain reserved for local small and medium enterprises. Establishing a PT PMA (foreign limited liability company) to hold licences and distribute is therefore legally feasible. The decisive questions are capital, KBLI coding, timeline and whether the product line justifies the fixed compliance cost of an own-entity structure, and each of these has concrete numbers attached that should be verified before funds are committed rather than after.

• Minimum paid-up capital for a PT PMA is IDR 2.5 billion (approximately USD 150,000, per BKPM-related rules); in practice the total investment plan per KBLI is usually not below IDR 10 billion (filed as a plan, not one-time paid-up capital).
• Both figures follow the current rules of the Ministry of Investment / BKPM and are subject to those rules.
• KBLI 2025 moved device wholesale from 46691 to 46791, with the full OSS switchover from 16 June 2026; retail corresponds to 47725; manufacturing spans 32501, 32502, 32509 and related codes.
• Pure company registration takes about 10 to 15 working days; where medical licences are involved (IDAK, CDAKB), plan for 6 to 9 months.
• The three most overlooked items: physical premises, the PJT notarial deed, and email and system consistency across OSS, Regalkes and KFA.

2. Legal basis

The ownership framework rests on the investment rules: pharmaceutical production and wholesale, device distribution, private hospitals and specialist clinics are open to 100 percent foreign shareholding, while primary clinics (Klinik Pratama) are reserved for local small and medium enterprises, and the PT PMA thresholds, including the IDR 2.5 billion minimum paid-up capital and the usual IDR 10 billion investment plan per KBLI, follow the current BKPM provisions, pending verification. On business classification, KBLI 2025 recodes device wholesale from 46691 to 46791 with the OSS switchover effective from 16 June 2026, retail sits under 47725, and manufacturing is distributed across 32501, 32502, 32509 and related codes; companies already registered in OSS must complete the code verification and update around the switchover or face system warnings or audit risk. Premises and PJT requirements derive from Permenkes No. 14/2021, and the CDAKB obligation from Permenkes No. 4/2014.

3. Expert insights

On timing, the gap between the two numbers is the whole story. Pure company registration takes about 10 to 15 working days, but where medical licences such as IDAK and CDAKB are involved, the realistic planning window is 6 to 9 months. The difference comes from physical premises preparation and acceptance, PJT staffing and registration, and the CDAKB quality system build and certification. A team that budgets the registration number alone will discover that the entity exists while the licences do not, which is precisely the idle state to avoid: the company is incorporated, IDAK does not come through, and no certificate can be submitted. The correct order is to treat the corporate registration as the first layer of a longer sequence, not as the milestone that matters, and to schedule the licence-critical workstreams in parallel with incorporation wherever the dependencies allow.

On the build-versus-appoint decision, the answer depends on product lines and the time window. Companies with multiple categories, a long-term commitment and annual sales sufficient to cover the fixed compliance costs of premises, personnel, CDAKB annual audits and a PJT suit an own-entity structure. Companies trialling a single category, or needing market entry within 6 months, should first appoint a qualified licence holder, obtain the certificate, and evaluate a self-build afterwards. Along the way, three items are most often neglected: IDAK does not accept virtual offices and the licence is bound to the registered address, so relocation requires a variation; the PJT cooperation agreement must be a notarial deed, effective since October 2024, with the technical person holding a relevant educational background; and entity information and email addresses must be consistent across OSS, Regalkes and KFA.

4. Practical recommendations

• Sequence the build deliberately: put premises, PJT and CDAKB in place first, then file the licence applications; establishing a shell company alone does not produce a licence.
• Budget 6 to 9 months for the licensed structure and treat the 10-to-15-working-day registration figure as only the corporate layer.
• Verify the PT PMA capital thresholds against current BKPM provisions before committing funds, since both the IDR 2.5 billion and IDR 10 billion figures are subject to those rules.
• Confirm the correct KBLI codes under KBLI 2025, moving wholesale from 46691 to 46791 ahead of the 16 June 2026 switchover, and check retail 47725 and manufacturing 32501, 32502, 32509 where relevant.
• Secure a physical office and warehouse meeting distribution standards before applying for IDAK, and plan any relocation as a formal variation to the licence.
• Execute the PJT cooperation agreement as a notarial deed and confirm the candidate’s educational background in pharmacy, electro-medical engineering, medical laboratory technology or public health.
• Align entity information and email addresses across OSS, Regalkes and KFA at the outset and after any corporate change.
• Reassess the build-versus-appoint decision annually against actual sales, since the fixed compliance cost of an own entity only pays back once the product line volume justifies it.

5. Verification checklist

• □ Confirm the investment rules on foreign shareholding and PT PMA thresholds against current BKPM provisions, pending verification.
• □ Confirm the KBLI 2025 code table, including 46791, 47725 and 32501, and the OSS switchover date of 16 June 2026.
• □ Confirm Permenkes No. 14/2021 on IDAK premises and PJT requirements, including the notarial deed effective from October 2024.
• □ Confirm Permenkes No. 4/2014 on the CDAKB obligation.
• □ Note that the timeline figures are industry experience values, pending verification against actual case processing.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Indonesia. Our team prepares dossiers to ASEAN CSDT structure, manages AKL/AKL-I submissions with Kemenkes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com